NASDAQ:BCYC Bicycle Therapeutics Q2 2025 Earnings Results & Report $3.60 +0.09 (+2.56%) Closing price 04:00 PM EasternExtended Trading$3.63 +0.03 (+0.78%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bicycle Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 8, 2025. The company reported EPS of -$1.14 versus the -$0.95 consensus estimate, while revenue of $2.90 million fell short of the $9.43 million estimate by $6.53 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 8, 2025TimeBefore Market OpensConference Call7:00 AM ET Bicycle Therapeutics EPS ResultsActual EPS-$1.14Consensus EPS -$0.95Beat/MissMissed by -$0.19One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersBicycle Therapeutics Revenue ResultsActual Revenue$2.90 millionExpected Revenue$9.43 millionBeat/MissMissed by -$6.53 millionYoY Revenue GrowthN/AUpcoming EarningsBicycle Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bicycle Therapeutics Q2 2025 Earnings FAQ Did Bicycle Therapeutics beat earnings estimates for Q2 2025? Bicycle Therapeutics (NASDAQ:BCYC) reported earnings of -$1.14 per share for Q2 2025, missing the consensus estimate of -$0.95. The report was announced on Friday, August 8, 2025. What was Bicycle Therapeutics' revenue for Q2 2025? Bicycle Therapeutics reported revenue of $2.90 million for Q2 2025, against a consensus estimate of $9.43 million. When is Bicycle Therapeutics' next earnings date? Bicycle Therapeutics' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bicycle Therapeutics on the company's earnings history page. Bicycle Therapeutics Earnings HeadlinesSpruce Biosciences (NASDAQ:SPRB) and Bicycle Therapeutics (NASDAQ:BCYC) Financial ComparisonOctober 11, 2026 | americanbankingnews.comHead-To-Head Survey: Bicycle Therapeutics (NASDAQ:BCYC) & Synlogic (NASDAQ:SYBX)October 5, 2026 | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Bicycle Therapeutics Ltd. ADRSeptember 24, 2026 | barrons.comRBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)August 5, 2026 | theglobeandmail.comVisa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatchAugust 3, 2026 | pymnts.comSee More Bicycle Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicycle Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicycle Therapeutics and other key companies, straight to your email. Email Address About Bicycle TherapeuticsBicycle Therapeutics (NASDAQ:BCYC) plc (NASDAQ:BCYC) is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines. The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics. Its pipeline has included programs directed at cancer-associated targets such as Nectin-4, with candidates designed to deliver cytotoxic payloads to tumor cells or activate the immune system in the tumor microenvironment. Bicycle Therapeutics also pursues research collaborations and licenses related to applications of its platform. Bicycle Therapeutics was founded in 2009 and has corporate and research operations in the United Kingdom and the United States, including Cambridge, England, and the Boston area. The company became publicly traded on Nasdaq in 2019. Its work is conducted through global clinical development, research and collaboration activities, and the company is led by Chief Executive Officer Kevin Lee.View Bicycle Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
